Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABA: Boswellic Acids in MS
NCT01450124Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2011
- Primary completion
- Dec 2014
- Modality
- NHE (Natural Herbal Extract)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of boswellia serrata in relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Mean number of total Gd-enhancing lesions at 8 months. Started Sep 2011; status: completed.
02
Drugs
boswellia serrata
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT01450124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450124.